97305-12-9 Usage
General Description
Ethyl 3-(2,6-difluorophenyl)-3-oxopropanoate is a chemical compound with the molecular formula C11H11F2O3. It is also known as ethyl 2,6-difluorophenyl glyoxylate and is commonly used in organic synthesis. ethyl 3-(2,6-difluorophenyl)-3-oxopropanoate is used as an intermediate in the production of various pharmaceuticals and agrochemicals. It has a faint odor and appears as a white solid at room temperature. The compound is stable under normal storage and handling conditions and can be hazardous if ingested or inhaled. It is important to handle and use ethyl 3-(2,6-difluorophenyl)-3-oxopropanoate with caution and according to proper safety procedures.
Check Digit Verification of cas no
The CAS Registry Mumber 97305-12-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,7,3,0 and 5 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 97305-12:
(7*9)+(6*7)+(5*3)+(4*0)+(3*5)+(2*1)+(1*2)=139
139 % 10 = 9
So 97305-12-9 is a valid CAS Registry Number.
97305-12-9Relevant articles and documents
HERBICIDAL CINNOLINE DERIVATIVES
-
Page/Page column 38-39, (2021/11/26)
Compounds of the Formula (I) wherein the substituents are as defined in claim 1. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling weeds, in particu
PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
-
Page/Page column 40; 41, (2010/09/17)
The present invention is directed to pyrazolo [4,3-c] cinnolin-3-one compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.